August 19, 2018


Current Projects

  1. Predictors of Refractory Ulcerative Colitis and its response to treatment
  2. Australian Ustekinumab Real-world Observational Research (AURORA)
  3. Fistulising Crohn’s Disease and Anti-TNF Level Study (FISCAL)
  4. Clinical factors associated with chronic inflammatory outcomes following ileal pouch-anal anastomosis for ulcerative colitis
  5. A cluster randomised controlled trial of a decision aid for ulcerative colitis patients: Enhancing patients’ quality of life, empowerment, quality of decision making and disease control (myAID)
  6. Efficacy of Infliximab and Adalimumab in the treatment of Crohn’s disease: factors that influence therapeutic outcomes in a large Australian and New Zealand patient cohort
  7. Retrospective observational cohort study of fertility intentions and of outcomes among women exposed to anti-TNF-α therapy for IBD
  8. ERA study: Intra-uterine exposure to anti-TNF-α therapy
  9. Success of endoscopic balloon dilatation in patients with stricturing Crohn’s disease
  10. Thiopurine Pathway Mathematical Model Project



  1. Krishnaprasad K, Walsh A, Begun J, et al. Crohn’s Colitis Care (CCCare): bespoke cloud-based clinical management software for Inflammatory Bowel Disease. Scand J Gastroenterol. 2020 Nov 8; 1-8.
  2. Flanagan E, Gibson PR, Wright EK, et al. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020 Nov;52(10):1551-1562.
  3. Pulusu, S. S. R., Srinivasan, A., Krishnaprasad, K., et al. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol. 2020 Aug 14;26(30):4428-4441.
  4. Wu Y, Ghaly S, Kerr S, et al. Level of UV Exposure, Skin Type, and Age Are More Important than Thiopurine Use for Keratinocyte Carcinoma Development in IBD Patients. Dig Dis Sci. 2019 Sep 6.
  5. Romagnoni A, Jégou S, Van Steen K, et al. Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Sci Rep. 2019 Jul 17;9(1):10351.
  6. Julsgaard M, Hvas CL, Gearry RB, et al. Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. Inflamm Bowel Dis. 2019 May 29.
  7. Momozawa Y, Dmitrieva J, Théâtre E, et al. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nat Commun. 2018 Jun 21;9(1):2427.
  8. Roberts RL, Wallace MC, Seinen ML, et al. Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 May 16.
  9. Chen GB, Lee SH, Montgomery GW, et al. Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method. BMC Med Genet. 2017 Aug 29;18(1):94.
  10. Huang H, Fang M, Jostins L, et al. Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature. 2017 Jun 28.
  11. Julsgaard M, Hvas CL, Gearry RB, et al. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Jul;23(7):1240-1246.
  12. Lawrance IC, Baird A, Lightower D, Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2017 Mar 7. pii: S1542-3565(17)30258-6.
  13. Doecke JD, Hartnell F, Bampton P, et al. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Aliment Pharmacol Ther. 2017 Feb;45(4):542-552. (First published: 19 December 2016)
  14. Ghaly S, Murray K, Baird A, Martin K, Prosser R, Mill J, Simms LA, Hart PH, Radford-Smith G, Bampton PA, Lawrance IC. High Vitamin D-Binding Protein Concentration, Low Albumin, and Mode of Remission Predict Relapse in Crohn's Disease. Inflamm Bowel Dis. 2016 Oct;22(10):2456-64.
  15. Li D, Achkar JP, Haritunians T, et al. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. Gastroenterology. 2016 Oct;151(4):724-32.
  16. Bodea CA, Neale BM, Ripke S; International IBD Genetics Consortium., Daly MJ, Devlin B, Roeder K. A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. Am J Hum Genet. 2016 May 5;98(5):857-68.
  17. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. 2016 Jul;151(1):110-9.
  18. Heap GA, So K, Weedon M, et al. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis. 2016 Feb;10(2):149-58.
  19. Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016 Jan 9;387(10014):156-67.
  20. Liu JZ, van Sommeren S, Huang H, at al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015 Sep;47(9):979-86.
  21. Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015 Feb;47(2):172-9.
  22. Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014 Sep 14.
  23. Roberts RL, Wallace MC, Seinen ML, et al. PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. Am J Gastroenterol. 2014 Jun;109(6):925-7.
  24. Chen GB, Lee SH, Brion MJ, et al. Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data. Hum Mol Genet. 2014 Sep 1;23(17):4710-20.
  25. Beaudoin M, Goyette P, Boucher G, et al. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet. 2013;9(9):e1003723.
  26. Lawrance IC, Murray K, Batman B, et al. Crohn’s disease and smoking: is it ever too late to quit? J Crohns Colitis. 2013 Dec 15;7(12):e665-71.
  27. Doecke JD, Simms LA, Zhao ZZ, et al. Genetic Susceptibility in IBD: Overlap between Ulcerative Colitis and Crohn’s Disease. Inflamm Bowel Dis. 2013 Feb;19(2):240-5.
  28. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 1;491(7422):119-24.
  29. Krishnaprasad K, Andrews JM, Lawrance IC, et al. Inter-observer agreement for Crohn’s disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian study. J Crohns Colitis. 2012 Apr;6(3):287-93.
  30. Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011 Oct 9;43(11):1066-73.
  31. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011 Mar;43(3):246-52.
  32. Rossin EJ, Lage K, Raychaudhuri S, et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet. 2011 Jan 13;7(1):e1001273.
  33. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010 Dec;42(12):1118-25.
  34. Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010 Nov;25(11):1732-8.